Patent: 9,334,319
✉ Email this page to a colleague
Summary for Patent: 9,334,319
Title: | Low acidic species compositions |
Abstract: | The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification. |
Inventor(s): | Ramasubramanyan; Natarajan (Westborough, MA), Yang; Lihua (Westborough, MA), Herigstad; Matthew Omon (Charlestown, MA), Yang; Hong (Worcester, MA), Chumsae; Christopher (North Andover, MA) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Application Number: | 13/829,989 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,334,319 |
Patent Claims: | see list of patent claims |
Details for Patent 9,334,319
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | December 31, 2002 | 9,334,319 | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | February 21, 2008 | 9,334,319 | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | April 24, 2013 | 9,334,319 | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | September 23, 2014 | 9,334,319 | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | November 23, 2015 | 9,334,319 | 2032-04-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |